



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : B.LALZAMLIANA, Drugs Inspector (F and D)
CMO West Office
Kulikawn, Aizawl- 796005
- Serial No. and date of Inspector's memorandum : B.11012/5/2024-CMO (W)/DRUGS/64 , 26-MAR-2025
- Number of Sample : SMP/MZ/TMT/2024-2025/062
- Date of receipt : 02-APR-2025
- Names of drugs purporting to be contained in the sample : Ferrous Sulphate and Folic Acid Tablets I.P.

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0547	GUW/LS/2025-26/545	CFR-W26	Mar-2024 Feb-2026	NA	Cyano Pharma (P) Ltd., 115-C, Industrial Estate, Pologround, Indore-452 015

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 29-May-2025 To 08-Jul-2025

COMPOSITION : Each sugar coated tablet contains: Dried Ferrous Sulphate IP 200 mg.
(Eq. to Ferrous Elemental Iron 60 mg.) Folic Acid I.P. 0.5 mg.

Protocol Applied : I.P.2022

Sr No.	Test Name	Result	Limits
1	Description	Red colored, round, bi-convex, coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Ferrous Sulphate and Folic Acid.	NA
3	Average weight	0.35523 g	NA
4	Disintegration	Complies. (Time taken for disintegration 44 minutes 56 seconds)	NMT 60 minutes
5	Uniformity of content	Complies for Folic Acid.	NA

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
-------	-----------------	-------	-------	------------	--------	--------------------

1	Dried Ferrous Sulphate equivalent to Elemental Iron	64.36 mg/Tablet	60 mg/Tablet	107.266	90 % to 110 %	I.P.2022
2	Folic acid	1.091 mg/Tablet	0.5 mg/Tablet	218.2	NLT 90 %	I.P.2022

In the opinion of the undersigned the sample referred to above is **of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P.2022 in respect of test performed.

Date: 06-AUG-2025

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
Guwahati-22

-----END OF REPORT-----

